AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28179024
Drug: Single annual
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single annual albendazole treatment
Trial: 22303641
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg kg(‐1) morphine
Trial: 9645635
Drug: 0.75% topical
RxNorm normalized name: Nydamax 0.75% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% topical metronidazole gel
Trial: 9645635
Drug: topical metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical metronidazole vehicle gel (placebo)
Trial: 2841172
Drug: Trimethoprim-polymyxin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-polymyxin B sulphate ophthalmic ointment (5 mg/g and 10,000 units/g)
Trial: 2841172
Drug: Chloramphenicol ophthalmic
RxNorm normalized name: chloramphenicol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol ophthalmic ointment (1%)
Trial: 29660670
Drug: Tilt group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilt group (passive tilting added to standardized rehabilitation therapy)
Trial: 29660670
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standardized rehabilitation therapy alone)
Trial: 23529918
Drug: Aerobic Exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic Exercise Training (AET) + Antihypertensive Drugs (ADs)
Trial: 23529918
Drug: Antihypertensive Drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive Drugs (ADs) alone
Trial: 18326592
Drug: TFAs from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFAs from natural sources (11-12 g/d, approximately 5% of daily energy)
Trial: 16566972
Drug: Antibiotics and
RxNorm normalized name: Antibiotics and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and prostatic massage (group 1: n = 17)
Trial: 16566972
Drug: Antibiotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics alone (group 2: n = 20)
Trial: 16566972
Drug: Antibiotics and
RxNorm normalized name: Antibiotics and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and prostatic massage (group 3: n = 25)
Trial: 16566972
Drug: Antibiotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics alone (group 4: n = 19)
Trial: 11902250
Drug: Continuous venovenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous venovenous hemofiltration (CVVH) at 2 L/hr for 48 hrs
Trial: 1693316
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with ifosfamide, cisplatin, and bleomycin (BIP) prior to radiotherapy
Trial: 6749634
Drug: Choleitholytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choleitholytic therapy
Trial: 30513347
Drug: Single-site bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-site bolus NGF injection (5 µg)
Trial: 30513347
Drug: Spatially distributed
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spatially distributed low-dose NGF injections (1 µg, 4 cm distance)
Trial: 30048048
Drug: Moderately rough
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately rough implant (Sa: 1.3 μm)
Trial: 30048048
Drug: Hybrid surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid surface implant (moderately rough implant body [Sa: 1.3 μm] and minimally rough implant neck [Sa: 0.9 μm])
Trial: 26205305
Drug: Process-based cognitive
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Process-based cognitive training (pb-CT) combined with reminiscence therapy (RT) for 3 months
Trial: 24254057
Drug: Barley oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barley oil supplements
Trial: 24254057
Drug: Palm oil
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palm oil supplements
Trial: 16286543
Drug: Topiramate (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (target dose, 400 mg/d in adults)
Trial: 10210384
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg furosemide on second visit
Trial: 10210384
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg furosemide on first visit
Trial: 350497
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g salsalate per day
Trial: 350497
Drug: 3.6 g
RxNorm normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g soluble aspirin per day
Trial: 29463421
Drug: HZ/su vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ/su vaccine
Trial: 23850262
Drug: ApoC-III in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApoC-III in VLDL (heparin-manganese precipitate)
Trial: 23850262
Drug: ApoC-III in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApoC-III in HDL (heparin-manganese supernatant)
Trial: 17241101
Drug: Supratherapeutic doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supratherapeutic doses of salbutamol (800-1200μg)
Trial: 17241101
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of salbutamol
Trial: 15570242
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH, 450 IU/kg/24 hr)
Trial: 15570242
Drug: Subcutaneous dalteparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dalteparin, 100 IU/kg given twice at a 12-hr interval
Trial: 15570242
Drug: Subcutaneous dalteparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dalteparin, 200 IU/kg given once
Trial: 15570242
Drug: Saline-solution infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline-solution infusion
Trial: 10228904
Drug: CA 125
RxNorm normalized name: ACA 125
DrugBank: ACA 125 (DB05489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA 125 screening with a cutoff value of 30 U/mL
Trial: 7611754
Drug: Intraarterial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarterial infusion of Epi‐adriamycin 30‐40 mg/body and CDDP 100 mg/body via reservoir every two weeks post‐operatively (group R)
Trial: 7611754
Drug: One-shot infusion
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-shot infusion of Epi‐adriamycin or adriamycin (group O)
Trial: 30753368
Drug: Human rotavirus
RxNorm normalized name: Live attenuated human Rotavirus RIX4414 strain Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human rotavirus vaccine (HRV)
Trial: 22393898
Drug: Bilastine 100
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Bilastine 100 mg
Trial: 21642470
Drug: Bilastine 20
RxNorm normalized name: Bilastine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilastine 20 mg with Ketoconazole 400 mg
Trial: 19473072
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program with low-level laser therapy (LLLT); 904-nm Ga-As laser in continuous mode, power density 130 mW/cm², dose 0.585 J/point.
Trial: 19473072
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program with polarized polychromatic non-coherent light (Bioptron 2); administered perpendicularly to the lateral epicondyle at three points for 6 min at each position.
Trial: 7760093
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg etomidate
Trial: 11136139
Drug: 0.05‐0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05‐0.1 mg/kg midazolam (control group)
Trial: 9633671
Drug: Tryptophan depletion
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan depletion (tryptophan-free amino acid beverage plus amino acid capsules)
Trial: 7020738
Drug: Busulphan treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulphan treatment
Trial: 7935995
Drug: Remission after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remission after busulphan treatment
Trial: 3346570
Drug: Q fever
RxNorm normalized name: Q fever
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q fever vaccine
Trial: 26993648
Drug: Large volumes
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large volumes of thin liquids (90 ml)
Trial: 24229481
Drug: Manualized psychodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized psychodynamic therapy (PDT)
Trial: 24229481
Drug: Waiting list/treatment-as-usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list/treatment-as-usual (WL/TAU)
Trial: 23537708
Drug: Etoposide in
RxNorm normalized name: etoposide Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide in combination with low-dose CAG (E-CAG)
Trial: 18188694
Drug: Lapatinib 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,250 mg/day plus capecitabine 2,000 mg/m2 days 1-14 of a 21-day cycle
Trial: 18188694
Drug: Capecitabine 2,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 2,500 mg/m2 on the same schedule
Trial: 16896785
Drug: Amlodipine-atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine-atorvastatin (10 mg + 20 mg)
Trial: 10992375
Drug: Indwelling catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indwelling catheter replacement before antimicrobial therapy
Trial: 10992375
Drug: No catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No catheter replacement before antimicrobial therapy
Trial: 3080269
Drug: Ibuprofen +
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen + Ethanol
Trial: 24195623
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Lactobacillus gasseri OLL2809
Trial: 24195623
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Lactobacillus gasseri OLL2809 + 900 mg α-lactalbumin
Trial: 12663512
Drug: Kiwifruit supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kiwifruit supplementation (specific dosage not mentioned) for 3-week periods
Trial: 12663512
Drug: Kiwifruit supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kiwifruit supplementation (specific dosage not mentioned)
Trial: 10887107
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of genetically modified CD8(+) T cells (10(10) cells)
Trial: 10887107
Drug: Second series
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second series of infusions of both CD4(+) and CD8(+) T cells engineered to express the chimeric receptor, costimulated ex vivo with beads coated with anti‐CD3 and anti‐CD28
Trial: 10887107
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of modified CD4(+) and CD8(+) T cells together after ex vivo costimulation
Trial: 8813788
Drug: High-dose preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose preoperative radiotherapy (5 x 5 Gy)
Trial: 31025930
Drug: tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tocilizumab 8 mg/kg intravenously at study begin and weeks 4, 8, and 12
Trial: 31025930
Drug: rituximab 1000
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab 1000 mg at weeks 16 and 18
Trial: 30334433
Drug: Oral Probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Probiotics
Trial: 27155493
Drug: PCV13 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 plus trivalent inactivated influenza vaccine
Trial: 22330975
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (short leg cast or brace and protected weight bearing for 6 weeks)
Trial: 16248728
Drug: Within-compound associations
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within-compound associations
Trial: 11790236
Drug: High-dose creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose creatine (150 mg/kg daily)
Trial: 8720287
Drug: Ribavirin alone
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin alone (15 mg/kg daily for 6 months)
Trial: 8720287
Drug: Interferon alone
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alone (3 MU thrice weekly for 6 months)
Trial: 8720287
Drug: Interferon plus
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon plus ribavirin (at above doses)
Trial: 1451730
Drug: 0.07 mg
RxNorm normalized name: urea 0.07 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg digitoxin o.d. for up to 58 days
Trial: 1451730
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral captopril b.d. (concomitant administration)
Trial: 29128648
Drug: ED-initiated Screening,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ED-initiated Screening, Brief Intervention, and Referral for Treatment (SBIRT) focused on HTN
Trial: 26179360
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec and insulin degludec/insulin aspart
Trial: 26179360
Drug: Basal‐oral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal‐oral therapy
Trial: 26179360
Drug: Type 2
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 2 diabetes multiple daily injections
Trial: 22471899
Drug: Topical fucidic
RxNorm normalized name: Fucidin Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fucidic acid plus betamethasone valerate cream
Trial: 22471899
Drug: Topical fucidic
RxNorm normalized name: Fucidin Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fucidic acid (control group)
Trial: 12755663
Drug: Ziprasidone (40-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (40-160 mg/day)
Trial: 15610070
Drug: Bosentan (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (500 mg orally 2 hours before ischaemia)
Trial: 12392582
Drug: Subcutaneous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous midazolam (0.1 mg kg‐1)
Trial: 12392582
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (0.1 mg kg‐1)
Trial: 7493374
Drug: 131I-labeled hMN-14
RxNorm normalized name: iobenguane (131I)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 131I-labeled hMN-14 IgG (8 to 30 mCi, 0.5 to 20.0 mg)
Trial: 7493374
Drug: hMN-14 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMN-14 (3 injections)
Trial: 7493374
Drug: Tumor radiation
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor radiation absorbed dose
Trial: 2372154
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg buprenorphine every 6 h for 36 h
Trial: 2372154
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg morphine every 6 h for 36 h
Trial: 6765526
Drug: Purified pork
RxNorm normalized name: Insulin purified pork
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Purified pork insulin preparation (regular and NPH insulin)
Trial: 6765526
Drug: Purified beef
RxNorm normalized name: Insulin purified beef
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Purified beef insulin (regular and NPH insulin)
Trial: 25654959
Drug: Levofloxacin (LFX)
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin (LFX) 500 mg o.d. with scaling and root planing (SRP)
Trial: 19106241
Drug: Higher insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher insulin dose
Trial: 17454224
Drug: L-arginine (20g/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (20g/500 mL intravenously daily for 5 days followed by 4 g/day orally for 2 weeks)
Trial: 15253854
Drug: Attitudes to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attitudes to Alternative Medicine Scale (pre-proving)
Trial: 15253854
Drug: Attitudes to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attitudes to Alternative Medicine Scale (post-proving)
Trial: 11238428
Drug: IEC interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IEC interventions with improved treatment of STDs
Trial: 2660551
Drug: Sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 2 g B.I.D.
Trial: 28537325
Drug: Calcium 1000
RxNorm normalized name: RITE AID Calcium 1000mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 1000 mg/d and cholecalciferol 800 IU for 3 years (intervention group)
Trial: 25482425
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg FXI‐ASO
Trial: 25482425
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg FXI‐ASO
Trial: 19366271
Drug: Candesartan/HCTZ 32/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan/HCTZ 32/25 mg
Trial: 16712531
Drug: Endotracheal intubation
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotracheal intubation attempted by paramedics without appropriate drugs to facilitate intubation.
Trial: 16712531
Drug: Intubation facilitated
RxNorm normalized name: ADAPTER,INTUBATION CAREFUSION #1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intubation facilitated by sedative drugs (but not relaxant drugs).
Trial: 11046203
Drug: Hetastarch (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetastarch (15 ml/kg, 6%)
Trial: 11046203
Drug: Albumin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin (15 ml/kg, 5%)
Trial: 8370687
Drug: Pamidronate (APD)
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate (APD) 30 mg, iv, daily for 2 days
Trial: 2942116
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol and ipratropium (combined treatment)
Trial: 2942116
Drug: Nebulised doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised doses (both treatments)
Trial: 20180613
Drug: Antidepressants (sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (sertraline or citalopram) with or without cognitive behavioral therapy
Trial: 20180613
Drug: Nonpharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic therapy (aerobic exercise)
Trial: 8561153
Drug: 14-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 1 day (n=10)
Trial: 8561153
Drug: 14-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 3 days (n=10)
Trial: 8561153
Drug: 14-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 5 days (n=10)
Trial: 8561153
Drug: 14-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 7 days (n=10)
Trial: 1888322
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (for treated phobics)
Trial: 1888322
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (for untreated phobics)
Trial: 1888322
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (for no-fear controls)
Trial: 7036285
Drug: Immunotherapy (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (combined BCG arms)